Innovating Works

NEUMACS

Financiado
Neuron associated macrophages in the gut as novel target for the treatment of en...
Neuron associated macrophages in the gut as novel target for the treatment of enteric neuropathies The gastrointestinal tract has the vital task to digest and absorb ingested food, a complex process requiring coordinated integration of motility, secretion, vascularization and absorption. Thereto the gastrointestinal tract is eq... The gastrointestinal tract has the vital task to digest and absorb ingested food, a complex process requiring coordinated integration of motility, secretion, vascularization and absorption. Thereto the gastrointestinal tract is equipped with its own nervous system, the enteric nervous system (ENS), capable of controlling gut function independently of input from brain or spinal cord. Reduction in number or dysfunction of the neurons within the gut wall, also referred to as enteric neuropathy, significantly impacts on gut function, resulting in stasis of luminal contents and malabsorption, chronic pain, vomiting, bloating and severe constipation. Enteric neuropathies are common in prevalent disorders such as obesity, diabetes, and ageing, all major contributors to the health burden. Despite the continuous global increase in incidence of these disorders, the insight in the mechanisms leading to the reduction or dysfunction of enteric neurons is limited and most importantly, adequate treatment is lacking. Recently, we collected evidence that survival of enteric neurons is guaranteed by a unique subpopulation of resident macrophages closely associated to the ENS and expressing a typical neuroprotective / -supportive transcriptome. In line, depletion of these neuron-associated macrophages (NA-MF) results in apoptosis and a reduction in number of enteric neurons leading to severely impaired gastrointestinal motility. We pose the provocative hypothesis that enteric neuropathy results from impaired support to the ENS by NA-MF, leading to neural distress and apoptosis. Using state-of-the-art methods, we will first characterize in depth the NA-MF population to subsequently unravel the mechanisms leading to failure of NA-MF to support and protect the ENS in animal models and in patients. These ground-breaking insights will allow us to identify therapeutic targets for the treatment of enteric neuropathies, representing an exponentially growing health problem of the 21st century. ver más
30/09/2024
KU Leuven
3M€
Duración del proyecto: 64 meses Fecha Inicio: 2019-05-10
Fecha Fin: 2024-09-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2024-09-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2018-ADG: ERC Advanced Grant
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 3M€
Líder del proyecto
KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5